神経治療学
Online ISSN : 2189-7824
Print ISSN : 0916-8443
ISSN-L : 2189-7824
シンポジウム10:核医学から迫る神経疾患の病態解明
神経伝達物質からみたParkinson病
三品 雅洋
著者情報
ジャーナル フリー

2020 年 37 巻 4 号 p. 611-613

詳細
抄録

Parkinson's Disease (PD) is a progressive degenerative neurological disorder characterized by resting tremor, bradykinesia, cogwheel rigidity, and postural instability. These symptoms result primarily from the loss of dopaminergic neurons in the substantia nigra. Positron emission tomography (PET) has enabled the acquisition of in vivo images of dopamine metabolism in patients with PD. Human endogenous dopamine level peaks at around 20 years old, and is decreased in 10 to 13% per decade of life. Some studies indicated that 80% loss of dopaminergic neurons in the substantia nigra was needed to develop symptoms of Parkinson's disease. Because many compensation systems are working against the decrease of dopamine. One of the most famous systems is acetylcholine. The striatal medium spiny neuron is regulated by dopaminergic input from substantia nigra pars compacta and cholinergic ineterneurons. Cholinergic interneurons occupy 1 to 2% of the neurons in the striatum. Nigral dopaminergic neurons suppress cholinergic interneurons in the striatum. In Parkinson's disease, the cholinergic system is relatively dominant because of degeneration of dopaminergic neurons. Anticholinergic reverses the balance of acetylcholine dominance. Using PET, we have shown that sigma1 and adenosine A2A receptors are involved in the compensation of dopamine deficiency.

著者関連情報
© 2020 日本神経治療学会
前の記事 次の記事
feedback
Top